<p>贝克顿，迪金森（NYSE: BDX）正在准备于 2026 年 2 月 9 日（星期一）公布其季度财报。以下是投资者在发布前应了解的简要概述。</p>
<p>分析师预计贝克顿，迪金森的每股收益（EPS）为 2.82 美元。</p>
<p>投资者对贝克顿，迪金森的公告充满期待，希望听到超出预期的消息以及对下个季度的积极指引。</p>
<p>新投资者应理解，虽然盈利表现很重要，但市场反应往往受到指引的驱动。</p>
<h3>盈利历史快照</h3>
<p>该公司在上个季度的每股收益超出预期 0.05 美元，导致次日股价上涨 0.25%。</p>
<p>以下是贝克顿，迪金森的过去表现及其价格变化：</p>
<table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第四季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 预估</strong></td>
<td align="right">3.91</td>
<td align="right">3.41</td>
<td align="right">3.28</td>
<td align="right">2.99</td>
</tr>
<tr>
<td><strong>EPS 实际</strong></td>
<td align="right">3.96</td>
<td align="right">3.68</td>
<td align="right">3.35</td>
<td align="right">3.43</td>
</tr>
<tr>
<td><strong>价格变化 %</strong></td>
<td align="right">0.00</td>
<td align="right">3.00</td>
<td align="right">0.00</td>
<td align="right">-7.00</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770386452_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="eps graph" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770386452_0.png"/></p>
<h3>股票表现</h3>
<p>截至 2 月 4 日，贝克顿，迪金森的股价为 206.51 美元。在过去 52 周内，股价下跌了 10.04%。鉴于这些回报通常是负面的，长期股东在此次财报发布前可能会感到有些不满。</p>
<h3>分析师对贝克顿，迪金森的看法</h3>
<p>对于投资者来说，掌握市场情绪和行业预期至关重要。本文分析了关于贝克顿，迪金森的最新见解。</p>
<p>贝克顿，迪金森获得了分析师的 5 个评级，普遍评级为中性。平均一年期目标价为 209.4 美元，表明潜在上涨 0.74%。</p>
<h3>行业同行评级比较</h3>
<p>以下是贝克顿，迪金森、IDEXX Laboratories、Edwards Lifesciences 和 ResMed 这三家行业知名公司的分析师评级和平均一年期目标价的比较，提供了它们相对表现预期和市场定位的见解。</p>
<ul>
<li>分析师目前对 IDEXX Laboratories 的表现持乐观态度，平均一年期目标价为 795.0 美元，表明潜在上涨 282.45%。</li>
<li>分析师目前对 Edwards Lifesciences 的表现持买入态度，平均一年期目标价为 97.35 美元，表明潜在下跌 53.17%。</li>
<li>分析师目前对 ResMed 的表现持中性态度，平均一年期目标价为 286.29 美元，表明潜在上涨 37.73%。</li>
</ul>
<h3>同行分析总结</h3>
<p>在同行分析总结中，展示了 IDEXX Laboratories、Edwards Lifesciences 和 ResMed 的关键指标，揭示了它们在行业中的地位，并提供了对其市场位置和相对表现的有价值见解。</p>
<table>
<thead>
<tr>
<th>公司</th>
<th>共识</th>
<th>收入增长</th>
<th>毛利润</th>
<th>股本回报率</th>
</tr>
</thead>
<tbody>
<tr>
<td>贝克顿，迪金森</td>
<td>中性</td>
<td>8.35%</td>
<td>28 亿美元</td>
<td>1.94%</td>
</tr>
<tr>
<td>IDEXX Laboratories</td>
<td>超越市场</td>
<td>-1.33%</td>
<td>6.8335 亿美元</td>
<td>15.68%</td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>买入</td>
<td>14.67%</td>
<td>12.1 亿美元</td>
<td>2.81%</td>
</tr>
<tr>
<td>ResMed</td>
<td>中性</td>
<td>10.98%</td>
<td>8.7872 亿美元</td>
<td>6.31%</td>
</tr>
</tbody>
</table>
<p>关键要点：</p>
<p>贝克顿，迪金森在同行中收入增长排名中等。与其他公司相比，其毛利润和股本回报率最低。</p>
<h3>揭示贝克顿，迪金森背后的故事</h3>
<p>贝克顿，迪金森是全球最大的医疗外科产品制造和分销商，产品包括针头、注射器和锐器处置单元。该公司还制造预填充设备、诊断仪器和试剂，以及流式细胞仪和细胞成像系统。BD Medical 几乎占总业务的一半，而 BD Life Sciences（2024 年收入的 26%）和 BD Interventional（25%）占据其余部分。国际收入占公司业务的 43%。</p>
<h3>理解数字：贝克顿，迪金森的财务状况</h3>
<p><strong>市值分析：</strong> 超过行业基准，该公司的市值强调了其显著规模，表明其强大的市场存在。</p>
<p><strong>收入增长：</strong> 在过去的 3 个月中，贝克顿，迪金森表现积极，截至 2025 年 9 月 30 日，其收入增长率为 <strong>8.35%</strong>。这反映了公司顶线收益的显著增长。与竞争对手相比，该公司面临困难，增长率低于医疗保健行业同行的平均水平。</p>
<p><strong>净利润率：</strong> 贝克顿，迪金森的净利润率令人印象深刻，超过行业平均水平。净利润率为 <strong>8.37%</strong>，表明公司盈利能力强，成本管理有效。</p>
<p><strong>股本回报率（ROE）：</strong> 该公司的 ROE 低于行业基准，表明在有效利用股本方面可能存在困难。ROE 为 <strong>1.94%</strong>，公司可能需要解决为股东创造满意回报的挑战。</p>
<p><strong>资产回报率（ROA）：</strong> 贝克顿，迪金森的 ROA 低于行业标准，表明在有效利用资产方面可能存在困难。ROA 为 <strong>0.89%</strong>，公司可能面临从其资产中提供满意回报的挑战。</p>
<p><strong>债务管理：</strong> 贝克顿，迪金森的债务与股本比率为 <strong>0.76</strong>，低于平均水平，采用谨慎的财务策略，表明其在债务管理方面采取了平衡的方法。</p>
<p>要跟踪贝克顿，迪金森的所有财报发布，请访问我们网站上的财报日历。</p>
<p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>

标普健康医疗设备 ETF - SPDR

碧迪医疗

美国医药设备 ETF - iShares

<p>碧迪医疗（Becton, Dickinson，纽约证券交易所代码：BDX）将于 2026 年 2 月 9 日公布季度财报，分析师预计每股收益（EPS）为 2.82 美元。该公司的分析师共识评级为中性，目标股价为 209.4 美元，显示出 0.74% 的潜在上涨空间。碧迪医疗的股价在过去一年下跌了 10.04%，在同行中其收入增长排名中等，增长率为 8.35%。该公司拥有强劲的净利润率为 8.37%，但与行业基准相比，股本回报率和资产回报率较低</p>

<p>Becton, Dickinson (NYSE: BDX) is gearing up to announce its quarterly earnings on Monday, 2026-02-09. Here's a quick overview of what investors should know before the release.</p>
<div class="lb-trans"><p>贝克顿，迪金森（NYSE: BDX）正在准备于 2026 年 2 月 9 日（星期一）公布其季度财报。以下是投资者在发布前应了解的简要概述。</p>
</div><p>Analysts are estimating that Becton, Dickinson will report an <strong>earnings per share</strong> (EPS) of $2.82.</p>
<div class="lb-trans"><p>分析师预计贝克顿，迪金森的每股收益（EPS）为 2.82 美元。</p>
</div><p>Anticipation surrounds Becton, Dickinson's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<div class="lb-trans"><p>投资者对贝克顿，迪金森的公告充满期待，希望听到超出预期的消息以及对下个季度的积极指引。</p>
</div><p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<div class="lb-trans"><p>新投资者应理解，虽然盈利表现很重要，但市场反应往往受到指引的驱动。</p>
</div><h3>Earnings History Snapshot</h3>
<div class="lb-trans"><h3>盈利历史快照</h3>
</div><p>The company's EPS beat by $0.05 in the last quarter, leading to a 0.25% increase in the share price on the following day.</p>
<div class="lb-trans"><p>该公司在上个季度的每股收益超出预期 0.05 美元，导致次日股价上涨 0.25%。</p>
</div><p>Here's a look at Becton, Dickinson's past performance and the resulting price change:</p>
<div class="lb-trans"><p>以下是贝克顿，迪金森的过去表现及其价格变化：</p>
</div><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q4 2025</strong></th>
<th align="right"><strong>Q3 2025</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">3.91</td>
<td align="right">3.41</td>
<td align="right">3.28</td>
<td align="right">2.99</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">3.96</td>
<td align="right">3.68</td>
<td align="right">3.35</td>
<td align="right">3.43</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">0.00</td>
<td align="right">3.00</td>
<td align="right">0.00</td>
<td align="right">-7.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第四季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 预估</strong></td>
<td align="right">3.91</td>
<td align="right">3.41</td>
<td align="right">3.28</td>
<td align="right">2.99</td>
</tr>
<tr>
<td><strong>EPS 实际</strong></td>
<td align="right">3.96</td>
<td align="right">3.68</td>
<td align="right">3.35</td>
<td align="right">3.43</td>
</tr>
<tr>
<td><strong>价格变化 %</strong></td>
<td align="right">0.00</td>
<td align="right">3.00</td>
<td align="right">0.00</td>
<td align="right">-7.00</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770386452_0.png" alt="eps graph" original-src="https://www.benzinga.com/files/images/story/2026/1770386452_0.png"/></p>
<h3>Stock Performance</h3>
<div class="lb-trans"><h3>股票表现</h3>
</div><p>Shares of Becton, Dickinson were trading at $206.51 as of February 04. Over the last 52-week period, shares are down 10.04%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.</p>
<div class="lb-trans"><p>截至 2 月 4 日，贝克顿，迪金森的股价为 206.51 美元。在过去 52 周内，股价下跌了 10.04%。鉴于这些回报通常是负面的，长期股东在此次财报发布前可能会感到有些不满。</p>
</div><h3>Analysts' Perspectives on Becton, Dickinson</h3>
<div class="lb-trans"><h3>分析师对贝克顿，迪金森的看法</h3>
</div><p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Becton, Dickinson.</p>
<div class="lb-trans"><p>对于投资者来说，掌握市场情绪和行业预期至关重要。本文分析了关于贝克顿，迪金森的最新见解。</p>
</div><p>Becton, Dickinson has received a total of 5 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $209.4, the consensus suggests a potential 0.74% upside.</p>
<div class="lb-trans"><p>贝克顿，迪金森获得了分析师的 5 个评级，普遍评级为中性。平均一年期目标价为 209.4 美元，表明潜在上涨 0.74%。</p>
</div><h3>Comparing Ratings Among Industry Peers</h3>
<div class="lb-trans"><h3>行业同行评级比较</h3>
</div><p>The below comparison of the analyst ratings and average 1-year price targets of IDEXX Laboratories, Edwards Lifesciences and ResMed, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<div class="lb-trans"><p>以下是贝克顿，迪金森、IDEXX Laboratories、Edwards Lifesciences 和 ResMed 这三家行业知名公司的分析师评级和平均一年期目标价的比较，提供了它们相对表现预期和市场定位的见解。</p>
</div><ul>
<li>Analysts currently favor an Outperform trajectory for IDEXX Laboratories, with an average 1-year price target of $795.0, suggesting a potential 282.45% upside.</li>
<li>Analysts currently favor an Buy trajectory for Edwards Lifesciences, with an average 1-year price target of $97.35, suggesting a potential 53.17% downside.</li>
<li>Analysts currently favor an Neutral trajectory for ResMed, with an average 1-year price target of $286.29, suggesting a potential 37.73% upside.</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师目前对 IDEXX Laboratories 的表现持乐观态度，平均一年期目标价为 795.0 美元，表明潜在上涨 282.45%。</li>
<li>分析师目前对 Edwards Lifesciences 的表现持买入态度，平均一年期目标价为 97.35 美元，表明潜在下跌 53.17%。</li>
<li>分析师目前对 ResMed 的表现持中性态度，平均一年期目标价为 286.29 美元，表明潜在上涨 37.73%。</li>
</ul>
</div><h3>Analysis Summary for Peers</h3>
<div class="lb-trans"><h3>同行分析总结</h3>
</div><p>Within the peer analysis summary, vital metrics for IDEXX Laboratories, Edwards Lifesciences and ResMed are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<div class="lb-trans"><p>在同行分析总结中，展示了 IDEXX Laboratories、Edwards Lifesciences 和 ResMed 的关键指标，揭示了它们在行业中的地位，并提供了对其市场位置和相对表现的有价值见解。</p>
</div><table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Becton Dickinson</td>
<td>Neutral</td>
<td>8.35%</td>
<td>$2.80B</td>
<td>1.94%</td>
</tr>
<tr>
<td>IDEXX Laboratories</td>
<td>Outperform</td>
<td>-1.33%</td>
<td>$683.35M</td>
<td>15.68%</td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>Buy</td>
<td>14.67%</td>
<td>$1.21B</td>
<td>2.81%</td>
</tr>
<tr>
<td>ResMed</td>
<td>Neutral</td>
<td>10.98%</td>
<td>$878.72M</td>
<td>6.31%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>公司</th>
<th>共识</th>
<th>收入增长</th>
<th>毛利润</th>
<th>股本回报率</th>
</tr>
</thead>
<tbody>
<tr>
<td>贝克顿，迪金森</td>
<td>中性</td>
<td>8.35%</td>
<td>28 亿美元</td>
<td>1.94%</td>
</tr>
<tr>
<td>IDEXX Laboratories</td>
<td>超越市场</td>
<td>-1.33%</td>
<td>6.8335 亿美元</td>
<td>15.68%</td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>买入</td>
<td>14.67%</td>
<td>12.1 亿美元</td>
<td>2.81%</td>
</tr>
<tr>
<td>ResMed</td>
<td>中性</td>
<td>10.98%</td>
<td>8.7872 亿美元</td>
<td>6.31%</td>
</tr>
</tbody>
</table>
</div><p>Key Takeaway:</p>
<div class="lb-trans"><p>关键要点：</p>
</div><p>Becton, Dickinson ranks in the middle for revenue growth among its peers. It has the lowest gross profit and return on equity compared to others.</p>
<div class="lb-trans"><p>贝克顿，迪金森在同行中收入增长排名中等。与其他公司相比，其毛利润和股本回报率最低。</p>
</div><h3>Unveiling the Story Behind Becton, Dickinson</h3>
<div class="lb-trans"><h3>揭示贝克顿，迪金森背后的故事</h3>
</div><p>Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.</p>
<div class="lb-trans"><p>贝克顿，迪金森是全球最大的医疗外科产品制造和分销商，产品包括针头、注射器和锐器处置单元。该公司还制造预填充设备、诊断仪器和试剂，以及流式细胞仪和细胞成像系统。BD Medical 几乎占总业务的一半，而 BD Life Sciences（2024 年收入的 26%）和 BD Interventional（25%）占据其余部分。国际收入占公司业务的 43%。</p>
</div><h3>Understanding the Numbers: Becton, Dickinson's Finances</h3>
<div class="lb-trans"><h3>理解数字：贝克顿，迪金森的财务状况</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 超过行业基准，该公司的市值强调了其显著规模，表明其强大的市场存在。</p>
</div><p><strong>Revenue Growth:</strong> Over the 3 months period, Becton, Dickinson showcased positive performance, achieving a revenue growth rate of <strong>8.35%</strong> as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> 在过去的 3 个月中，贝克顿，迪金森表现积极，截至 2025 年 9 月 30 日，其收入增长率为 <strong>8.35%</strong>。这反映了公司顶线收益的显著增长。与竞争对手相比，该公司面临困难，增长率低于医疗保健行业同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Becton, Dickinson's net margin is impressive, surpassing industry averages. With a net margin of <strong>8.37%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> 贝克顿，迪金森的净利润率令人印象深刻，超过行业平均水平。净利润率为 <strong>8.37%</strong>，表明公司盈利能力强，成本管理有效。</p>
</div><p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.94%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> 该公司的 ROE 低于行业基准，表明在有效利用股本方面可能存在困难。ROE 为 <strong>1.94%</strong>，公司可能需要解决为股东创造满意回报的挑战。</p>
</div><p><strong>Return on Assets (ROA):</strong> Becton, Dickinson's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.89%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> 贝克顿，迪金森的 ROA 低于行业标准，表明在有效利用资产方面可能存在困难。ROA 为 <strong>0.89%</strong>，公司可能面临从其资产中提供满意回报的挑战。</p>
</div><p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.76</strong>, Becton, Dickinson adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> 贝克顿，迪金森的债务与股本比率为 <strong>0.76</strong>，低于平均水平，采用谨慎的财务策略，表明其在债务管理方面采取了平衡的方法。</p>
</div><p>To track all earnings releases for Becton, Dickinson visit their earnings calendar on our site.</p>
<div class="lb-trans"><p>要跟踪贝克顿，迪金森的所有财报发布，请访问我们网站上的财报日历。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>
</div>

碧迪医疗即将发布的财报概览